A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion

Inclusion Criteria:

* Participants with advanced solid tumors diagnosed by histopathology or cytopathology.
* Moderate to large pleural effusions require intervention.
* ECOG performance status: 0 to 2.
* Life expectancy ≥ 3 months
* Adequate organ function.
* The serum pregnancy test of female participants of childbearing potential should be negative within 7 days prior to enrollment and must not be breastfeeding. With a fertile female/male must agree to use medically accepted non-pharmacological contraception during the study and for 6 months after the last dose.

Exclusion Criteria:

* Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.
* Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.
* Known allergies to the study drug or its excipient components.
* Have participated in other clinical trials within 28 days prior to randomization.
* Major surgery within 28 days prior to randomization.
* Central nervous system metastatic disease, leptomeningeal disease, or cord compression.
* Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.
* Active infections that require systemic treatment.
* Have a history of organ transplantation.
* Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.